In a recent study, gemticabine- and cisplatin-resistant RT112 BC cells were verified to have enhanced cIAP1/2 and XIAP expression and to be cross-resistant to TRAIL-mediated apoptosis. This evidence concerns the gene XIAP and breast cancer.